Expression and clinical significance of wnt players and survivin in pituitary tumours

Endocrine Pathology

Volumn 23, Issue 2, 2012, Pages 123-131

  Formosa, Robert ^b   Gruppetta, Mark ^a,b   Falzon, Sharon ^a   Santillo, Graziella ^a   DeGaetano, James ^a   Xuereb Anastasi, Angela ^b   Vassallo, Josanne ^a,b  

^a MATER DEI HOSPITAL   (Malta)

^b UNIVERSITY OF MALTA   (Malta)

Author keywords

catenin; Cyclin D1; Myc; Pituitary; Survivin; Wnt

Indexed keywords

BETA CATENIN; CYCLIN D1; MYC PROTEIN; OCTREOTIDE; SURVIVIN; WNT PROTEIN;

ADULT; ARTICLE; CARCINOGENESIS; COMORBIDITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TISSUE CHARACTERIZATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BETA CATENIN; COMBINED MODALITY THERAPY; CYCLIN D1; FEMALE; HUMANS; HYPOPITUITARISM; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTINOMA; PROTO-ONCOGENE PROTEINS C-MYC; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84864854700     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-012-9197-8     Document Type: Article

References (57)

1. Boikos SA & Stratakis CA. Molecular Genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumor-igenesis. Human Molecular Genetics. 16 (1) R80-R87, 2007.
2. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R & Ben-Ze'ev A. The Cyclin D1 gene is a target of the B-catenin/LEF-1 pathway. PNAS, 96: 5522-5527, 1999.
3. Polakis P. Wnt signaling and cancer. Genes & Development. 14: 1837-1851, 2000.
4. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, Tang N, Haydon RC, Luu HH & He TC. Wnt signaling and human diseases: what are the therapeutic implications? Laboratory Investigation, 87: 97-103, 2007.
5. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJJ, Cook RJ, Little NC, Clifton-Bligh RJ, Robinsom BG & McDonald KL. Wnt Pathway Inhibitors Are Strongly Down-Regulated in Pituitary Tumours. Endocrinology, 149 (2): 1235-1242, 2008.
6. Jiang Z, Gui S & Zhang Y. Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas. Endocrine. 38 (3): 360-368, 2010.
7. Gaston-Massueta C, Andoniadoua CL, Signorea M, Jayakodya SA, Charolidia N, Kyeyuneb R, Vernaya B, Jacquesa TS, Taketoc MM, Le Tissierd P, Dattanie MT & Martinez-Barberaa JP. Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. PNAS. 108 (28): 11482-11487, 2001.
8. Geourguiev M & Grossman AB. Pituitary gland and ß-catenin signaling: from ontogeny to oncogenesis. Pituitary. 12: 245-255, 2009.
9. Sun C, Yamato T, Kondo E, Furukawa T, Ikeda H, Horii A. Infrequent mutation of APC, AXIN1, and GSK3B in human pituitary adenomas with abnormal accumulation of CTNNB1. Journal of Neuro-oncology 73 (2): 131-134, 2005.
10. Semba S, Han S, Ikeda H & Horii A. Frequent Nuclear Accumulation of B-catenin in Pituitary Adenoma. Cancer, 91 (1): 42-48, 2001.
11. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro R, Horiguchi H, Wakatsuki S, Hirokawa M, & Sano T. Role of E-Cadherin, a-, ß-, and y-Catenins, and p120(Cell Adhesion Molecules) in Prolactinoma Behavior. Modern Pathology. 15 (12): 1357-1365.
12. Xu B, Sano T, Yoshimoto K & Yamada S. Downregulation of E-cadherin and undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocrine Pathology. 13 (4): 341-351, 2002.
13. Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M & Adams EF. Beta-catenin mutation in craniopharyngiomas and pituitary adenomas. J Neurooncol, 73 (3): 205-209, 2005.
14. Tziortzioti V, Ruebel KH, Kuroki T, Jin L, Scheithauer BW & Lloyd RV. Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol, 12 (2): 125-136, 2001.
15. Howng SL, Wu CH, Cheng TS, Sy WD, Lin PK, Wang C & Hong YR. Differential expression of Wnt genes, ß-catenin and E-cadherin in brain tumours. Cancer Letters. 183 (1): 95-101, 2002.
16. Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J & Fahlbusch R. Common mutations of ß-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Nueropathologica. 109: 589-597, 2005.
17. Sherr CJ. D-type Cyclins. Trends Biochem Sci, 20 (5): 187-190, 1995.
18. Klein EA & Assoian RK Transcriptional regulation of the Cyclin D1 gene at a glance. Journal of Cell Science. 121; 3853-3857, 2008.
19. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN & Farrell WE. Analysis of Cyclin D1 (CCND1) Allelic Imbalance and Overexpression in sporadic Human Pituitary Tumors. Clinical Cancer Research. 5: 2133-2139, 1999.
20. Gazioglu N, Erensoy N, Kadioglu P, Sayitoglu MA, Ersoy IH, Hatirnaz O, Kisacik B, Oz B, Sar M, Ozbek U, Ciplak N & Cagatay P. Altered cyclin D1 genotype distribution in human sporadic pituitary adenomas. Medical Science Monitor. 13 (10): CR-457-463, 2007
21. Qian X, Kulig E, Jin L & Lloyd RV. Expression of D-Type Cyclins in Normal and Neoplastic Rat Pituitary. Endocrinology. 139 (4): 2058-2067, 1998.
22. Saeger W, Schreiber S & Ludecke DK. Cyclins D1 and D3 and Topoisomerase IIa in Inactive Pituitary Adenomas. Endocrine Pathology. 12 (1): 39-47, 2001.
23. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M & Grossman AB. Activation ofRAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-Related Cancer. 16: 132901338, 2009.
24. Jordan S. Lidhar K, Korbonits M, Lowe DG & Grossman AB. Cyclin D and Cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology. 143 (1): R1-R6, 2000.
25. Kremenevskaya N, Khattak MN & Buchfelder M. The Involvement of the Wnt/beta-catenin pathway in pituitary adenomas. Abstract presented at the 58th Annual Meeting of the German Society of Neurosurgery, 2007
26. Wang DG, Johnston CF, Atkinson AB, Heaney AP, Mirakhur M. & Buchanan FD. Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc. J Clin Pathol. 49; 795-797, 1996.
27. Woloschak M, Roberts JL, Post K. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas. JCEM, 79 (1): 253-257, 1994.
28. Macchiavelli GA, Rivolta CM, Artese R, Basso A & Burdman JA. Expression of c-myc and c-fos and binding sites for estradiol and progesterone in human pituitary tumors. Neurol Res. 20 (8): 709-712, 1998
29. Raghanan R, Harrison D, Ince PG, James RA, Daniels M, Birch P, Caldwell GI & Kendall-Taylor P. Oncoprotein Immunoreactivity in human pituitary tumours. Clinical Endocrinology. 40 (1): 117-126, 1994.
30. Ghosh JC, Dohi T, Kang BH & Altieri DC. Hsp60 REGULATION OF TUMOR CELL APOPTOSIS. Journal of Biological Chemistry, 283 (8), 5188-5194, 2008.
31. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Research, 5: 447-452, 2003.
32. Ku JH, Kwak C, Lee HS, Park HK, Lee E & Lee Se. Expression of Survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Journal of Urology, 171: 631-635, 2004.
33. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y & Kaibara N. Expression of Survivin messenger RNA correlated with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol, 11 (1): 33-49, 2002.
34. Wasko R, Waligorska-Stachura J, Jankowska A, Warchol JB, Liebert W & Sowinski J. Coexpression of Survivin and PCNA in pituitary tumors and normal pituitary. Neuro Endocrinol Lett. 30(4): 477-481, 2009.
35. Hassounah M, Lach B, Allam A, Al-Khalaf H, Siddiqui Y, Pangue-Cruz N, Al-Omeir A, Al-Ahdal M & Aboussekhra A. Benign tumors from the human nervous system express high levels of Survivin and are resistant to spontaneous and radiation-induced apoptosis. Journal of Neuro-Oncology. 72: 203-208, 2005.
36. Zhang YC, Gao J, Xin T, Zheng ZM, Teng LZ. Expression of Survivin in invasive pituitary adenoma. Saudi Med J. 29 (11): 1589-1592, 2008.
37. Jankowska A, Wasko R, Waligorska-Stachura J, Andrusiewicz M, Jaskula M, Liebert W & Sowinski J. Survivin products in pituitary tumours. Neuro Endocrinol Lett. 29 (6):1033-1037, 2008.
38. Kang BH & Altieri DC. Regulation of Survivin stability by the aryl hydrocarbon receptor-interacting protein. The Journal of Biological Chemistry, 201 (34): 24721-24727, 2006.
39. Kang BH, Xia F, Pop R, Dohl T, Socolovsky M & Altieri DC. Developmental control of apoptosis by the immunophilin aryl hydrocardbon receptor-interacting protein (AIP) involves mitochondrial import of the Survivin protein. J Biol Chem. 286 (19): 16758-16767, 2011.
40. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF. Overexpression of Cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res, 5: 2069-2076, 1999.
41. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by Cyclin D1. Cell. 88 (3): 405-415, 1997.
42. Knudsen KE, Cavenee WK, Arden KC. D-type Cyclins complex with the androgen receptor and inhibit its transcriptional trans-activation ability. Cancer Research. 15 (59): 2297-2301, 1999.
43. Zhan X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bron-stein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. JCEM, 84 (2): 761-767, 1999.
44. Pei L. Identification of c-myc as a downstream target for Pituitary Tumor-Transforming Gene. The Journal of Biological Chemistry. 276 (11): 8481-8491, 2001.
45. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC & Lobie PE. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Research. 65(1): 317-324, 2005.
46. Hällstrom IP, Gustafsson JA & Blanck. Hypothalamo-pituitary regulation of the c-myc gene in rat liver. Journal of Molecular Endocrinology. 5:267-274, 1990.
47. Hällstrom IP, Gustafsson JA & Blanck A. Effects of growth hormone on the expression of c-myc and c-fos during early stages of sex-differentiated rat liver carcinogenesis in the resitatant hepatocyte model. Carcinogenesis. 10 (12): 2339-2343, 1989.
48. Fleming WH, Murphy PR, Murphy LJ, Hatton TW, Matusik RJ & Friesen HG. Human growth hormone induces and maintains c-myc gene expression in Nb2 lymphoma cells. Endocrinology. 117 (6): 2547-2549, 1985.
49. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med, 8 (6): 446-458, 2008.
50. Neiman PE, Elsaesser K, Loring G & Kimmel R. Myc oncogene-induced genomic instability: DNA palindromes in bursal lymphomagenesis. PLoS Genetics, 4 (7): e1000132, 2008.
51. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM & Monson JP. Predicting Therapeutic Response and Degree of Pituitary Tumour Shrinkage during Treatment of Acromegaly with Octreotide LAR. Hormone Research in Paediatrics. 62 (5)227-232, 2004.
52. Vance ML & Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide: result of the international multicenter acromegaly study group. Arch Intern Med. 151: 1573-1578, 1991.
53. Asa SL, Felix I, Kovacs K & Ramyar L. Effects of somatostatin on somatotroph adenomas of the human pituitary: an in vitro functional and morphological study. Endocrine Pathology. 1: 236-244, 1990.
54. Pelicci G, Pagliacci LC, Lanfrancone L, Pelicci PG, Grignani E & Nicoletti I. Inhibitory effect of the somatostatin analogue octreo-tide on rat pituitary tumor cell (GH3) proliferation in vitro. J Endocrinol Invest. 13 (8): 657-662, 1990.
55. Chen JS, Liang QM, Li HS, Yang J, Wang S & Long JW. Octreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt/β-catenin pathway. Pharmazie. 64 (2): 126-131, 2009.
56. Molitch ME. Clinical manifestations of acromegaly. Endocrinology and metabolism clinics of North America. 21 (3): 597-614, 1992.
57. Vierimaa O, Goergitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A & Aaltonen LA. Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene. Science, 312, 1128-1230, 2006.